

Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches

Kamila Stránská^{1,2,3}, Jana Štrignerová², Kristýna Taušová^{1,2,3}, Jana Bruknerová^{2,3}, Hana Skuhrová Francová¹, Jakub Paweł Porc^{2,3}, Tomáš Reigl^{2,3}, Veronika Navrkalová^{1,2,3}, Yvona Brychtová¹, Anna Panovská¹, Michael Doubek^{1,2,3}, Šárka Pospíšilová^{1,2,3}, Karla Plevová^{1,2,3}

1 - Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; 2 - Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic


3 - CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic

BACKGROUND


Chronic lymphocytic leukemia (CLL) is typically characterized by the presence of a dominant B-cell clone with a unique immunoglobulin heavy-chain (IGH) gene rearrangement. However, a subset of patients exhibits multiple clonal IGH rearrangements, indicating underlying multiclonality. At the single cell level, we have demonstrated that each productive IGH gene rearrangement (P-IGH) represents a distinct B-cell clone [1]. Shifts in clonal ratios have been observed [2] highlighting the importance of their monitoring. Understanding of clonal architecture and its evolution over time is essential for insights into disease biology and progression. Here we employ capture-based and amplicon NGS approaches and compare their results with traditional Sanger sequencing.

RESULTS

1) Routine IGHV examination (Sanger)




3) Multiclonal CLL: LYNX and IGH NGS



METHODS

PATIENTS




2) Multiclonal CLL: Evolution over time (Sanger)

- 100 multiclonal patients: IGHV examination performed repeatedly over time (first-last examination: median 3.4 years)
- one or more clones disappeared: 53/100 (53%) patients
- new clone emerged later: 21/100 (21%) patients — 17/21 were monoclonal at dg
- dominant clone replaced by another: 5 patients

if >5 clonotypes with size 0.2-1% identified, new clones were assigned above 5% cut-off

4) Monoclonal CLL: IGH NGS



SANGER SEQUENCING

- cDNA
- PCR amplification, fragment analysis, cloning if needed
- L-C primers; IGHV family singleplexes + multiplex



CAPTURE-BASED NGS PANEL LYNX [3]

- DNA
- capture with probes, amplification with UMIs
- whole IGH sequence FR1-junction can be obtained
- analyzed with LYNX online tool
- typically hundreds of fragments (unique molecules) covering IGHV-D-J
- clonal productive IGH rearrangement (P-IGH) cut-off: 1% of fragments covering IGHV-D-J; 3 fragments

AMPLICON IGH NGS [4]

- DNA
- PCR amplification
- L-J primers; multiplex
- bioinformatics analysis: Interrogate amplicon mode
- typically millions of usable reads
- clonal P-IGH cut-off: 1% of reads

CONCLUSION

Our results provided a comprehensive assessment of clonality in the analyzed multiclonal CLL cases, with a notable prevalence of concordant IGHV mutational status among co-detected clones. Detecting minor clones in multiclonal CLL remains challenging, as the sensitivity of detection varies across different approaches. The clinicobiological significance of minor clones is still unclear and warrants further investigation.

REFERENCES

- Brazdilova et al, Leukemia 2018
- Plevová et al, Haematologica 2014
- Navrkalová et al, J Mol Diagn 2021
- Langlois de Septenville, Methods in Molecular Biology, 2022



CONTACT DETAILS
stranska.kamila@fnbrno.cz

ACKNOWLEDGEMENT
Funded by: MH CZ AZV NW24-03-00052 and RVO FNbr65269705; MEYS CZ MUNI/1685/2024 and NICR LX22NPO5102 - Funded by the European Union - Next Generation EU. Computational resources were provided by the e-INFRA CZ project (ID:90254), supported by MEYS CZ